The forecast for nervous system medicine sales in Italy suggests a gradual decline from 2024 to 2028, with a decrease from $2.01 billion in 2024 to $1.82 billion in 2028. This indicates a consistent year-on-year decrease, with percentage variations showing a steady decline of approximately -2.5% annually. Compared to 2023 sales data, this suggests a challenging market environment. Over the last five years, the compound annual growth rate (CAGR) highlights a persistent downturn averaging -2.5% each year.
Future trends to watch for include:
- Technological advancements in treatment options.
- Regulatory changes impacting drug approval processes.
- Shifting demographics and aging populations potentially increasing demand.
- Price regulation and reimbursement policies in Italy.
- Innovations in generic and biosimilar medicines.
